EVAXION BIOTECH A/S (EVAX) Stock Analyst Ratings
NASDAQ:EVAX - Nasdaq - US29970R2040 - ADR - Currency: USD
ChartMill assigns a Buy % Consensus number of 84% to EVAX. The Buy consensus is the weighted average rating of the current analysts ratings.
EVAX was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about EVAX.
In the previous month the buy percentage consensus was at a similar level.
EVAX was analyzed by 9 analysts. More opinions would make the average more meaningful.
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2024-11-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-26 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-09-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-16 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-01 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-03 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-04-02 | Ladenburg Thalmann | Upgrade | Neutral -> Buy |
| 2024-03-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-02-12 | HC Wainwright & Co. | Initiate | Buy |
| 2023-12-21 | Ladenburg Thalmann | Downgrade | Buy -> Neutral |
| 2023-03-31 | Lake Street | Maintains | Buy |
| 2022-11-17 | Oppenheimer | Maintains | Outperform |
| 2021-03-02 | Oppenheimer | Initiate | Outperform |